• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RAPT

    RAPT Therapeutics Inc.

    Subscribe to $RAPT
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: rapt.com

    Recent Analyst Ratings for RAPT Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    12/26/2024$10.00Neutral → Buy
    H.C. Wainwright
    11/13/2024$7.00 → $2.00Buy → Hold
    Stifel
    11/11/2024$8.00 → $2.00Overweight → Neutral
    Piper Sandler
    11/11/2024Neutral → Underweight
    JP Morgan
    5/14/2024Outperform → Peer Perform
    Wolfe Research
    5/10/2024Buy → Neutral
    Guggenheim
    5/10/2024$13.00 → $4.00Overweight → Equal Weight
    Barclays
    2/22/2024$61.00 → $10.00Buy → Neutral
    UBS
    2/21/2024$42.00 → $10.00Outperform → Market Perform
    Leerink Partners
    2/21/2024$35.00 → $15.00Overweight → Neutral
    JP Morgan
    See more ratings

    RAPT Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Robbins Wendye

      4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

      4/2/25 9:08:06 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gray Mary Ann

      4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

      4/2/25 8:40:32 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF MEDICAL OFFICER Ho William

      4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

      2/3/25 6:26:08 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF FINANCIAL OFFICER Young Rodney Kb

      4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

      2/3/25 6:24:55 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Brockstedt Dirk G.

      4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

      2/3/25 6:23:37 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT AND CEO Wong Brian Russell

      4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

      2/3/25 6:22:06 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Medicxi Ventures Management (Jersey) Ltd claimed ownership of 22,352,000 shares (SEC Form 3)

      3 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

      1/6/25 9:12:24 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Former 10% Owner Column Group Ii, Lp disposed of 2,951,425 shares (SEC Form 4)

      4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

      12/23/24 5:59:39 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Former 10% Owner Column Group Ii, Lp disposed of 2,951,425 shares (SEC Form 4)

      4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

      12/23/24 5:57:58 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF FINANCIAL OFFICER Young Rodney Kb

      4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

      11/15/24 8:00:19 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    RAPT Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

      SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

      11/14/24 1:22:39 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

      SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

      11/14/24 9:39:56 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

      SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

      11/12/24 4:59:18 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

      SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

      11/12/24 10:34:17 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

      SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

      11/4/24 1:30:15 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by RAPT Therapeutics Inc. (Amendment)

      SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

      2/14/24 4:41:59 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by RAPT Therapeutics Inc. (Amendment)

      SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

      2/14/24 4:26:22 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by RAPT Therapeutics Inc. (Amendment)

      SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

      2/14/24 10:03:05 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by RAPT Therapeutics Inc. (Amendment)

      SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

      2/14/24 8:52:45 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by RAPT Therapeutics Inc.

      SC 13G - RAPT Therapeutics, Inc. (0001673772) (Subject)

      2/13/24 5:12:21 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    RAPT Therapeutics Inc. Financials

    Live finance-specific insights

    See more

    RAPT Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

      - RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales - - Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China - - RAPT plans to initiate Phase 2b trial in food allergy next year - - RAPT to host a conference call at 8:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patient

      12/23/24 7:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

      - RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the company's Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma. The company expects to receive a formal clinical hold letter from

      2/20/24 7:30:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

      - Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 positive patients at time of data cut off - Confirmed ORR of 50% in patients with PD-L1 high expression (TPS ≥50%) and 38% in patients with PD-L1 low expression (TPS 1-49%) - RAPT to host webcast conference call today at 10:00 am PT SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with s

      11/3/23 12:00:00 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

      SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E ("IgE"), a key driver of several allergic diseases. RAPT plans to pursue development of RPT904 initially in food allergy and chronic spontaneous urticaria ("CSU").

      4/15/25 8:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

      SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

      1/6/25 8:00:00 AM ET
      $CTNM
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

      SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations. "I am delighted to announce the addition of Nipun to the RAPT leadership team and welcome his wealth of experience in small molecule product development and commercial manufacturing," said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeu

      2/13/24 8:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

      SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Michael Listgarten as General Counsel. "I'm excited to welcome Michael to the RAPT leadership team," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "As we advance from development toward potential commercialization, Michael's deep legal expertise and organizational leadership experience from a broad spectrum of biopharmaceutica

      5/3/23 8:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires

      SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Jennifer Nicholson as Senior Vice President of Regulatory Affairs and Quality Assurance and Adnan Rahman as Vice President of Commercial. "It is a pleasure to welcome both Jennifer and Adnan to the RAPT leadership team at this exciting time of growth for the Company," said Brian Wong, M.D., Ph.D., President and Chief Executive Off

      9/28/22 8:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Lori Lyons-Williams, a 20-year industry veteran, to its Board of Directors. "We are very excited to welcome Lori to RAPT's board of directors," said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics. "Her strong track record of driving strategic and commercial success across both biotech and pharmaceutical products wi

      11/9/21 4:01:00 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    RAPT Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RAPT Therapeutics Reports First Quarter 2025 Financial Results

      SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT" or the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the first quarter ended March 31, 2025. "The year is off to a great start. We believe RPT904 has the potential to be a best-in-class option to treat patients with food allergy and are making good progress toward our planned initiation of a Phase 2b trial in the second half of 2025," said Brian Wong, President and CEO of RAPT. "We are

      5/8/25 8:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

      SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E ("IgE"), a key driver of several allergic diseases. RAPT plans to pursue development of RPT904 initially in food allergy and chronic spontaneous urticaria ("CSU").

      4/15/25 8:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics to Participate in Upcoming Investor Conferences

      SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March: Leerink Global Healthcare Conference – Fireside chat on Tuesday, March 11, 2025 at 3:40 p.m. ET Barclays 27th Annual Global Healthcare Conference – Fireside chat on Wednesday, March 12, 2025 at 10:30 a.m. ET To access the live webcasts or subsequent archived recor

      3/7/25 4:30:08 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

      SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT" or the "Company") is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the fourth quarter and year ended December 31, 2024. "Our focus for 2025 will be on advancing development of RPT904, a novel, potential best-in-class option to treat the large and underserved population of patients suffering from food allergy and chronic spontaneous urticaria," said Brian Wong, President and CEO of RAPT. "We belie

      3/6/25 8:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacific Time. To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-pres

      1/9/25 8:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

      SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

      1/6/25 8:00:00 AM ET
      $CTNM
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Announces $150 Million Private Placement

      SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 100,000,000 shares of common stock at a purchase price of $0.85 per share and (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 76,452,000 shares of common stock at a price per pre-funded warrant of $0.8499,

      12/23/24 7:10:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

      - RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales - - Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China - - RAPT plans to initiate Phase 2b trial in food allergy next year - - RAPT to host a conference call at 8:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patient

      12/23/24 7:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Reports Third Quarter 2024 Financial Results

      SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the third quarter and nine months ended September 30, 2024. Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 Third Quarter Ended September 30, 2024 Net loss for the third quarter of 2024 was $18.4 million, compared to $31.4 million for the third quarter of 2023. Research and development expenses for

      11/12/24 8:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

      SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it is terminating its zelnecirnon (RPT193) program. Zelnecirnon was being evaluated in two randomized, placebo-controlled Phase 2 clinical trials in asthma and atopic dermatitis (AD), and both trials were placed on clinical hold by the U.S. Food and Drug Administration (FDA) in February 2024 due to a serious adverse event (SAE) of liver injury requiri

      11/11/24 8:00:00 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    RAPT Therapeutics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by RAPT Therapeutics Inc.

      10-Q - RAPT Therapeutics, Inc. (0001673772) (Filer)

      5/8/25 8:07:16 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RAPT Therapeutics, Inc. (0001673772) (Filer)

      5/8/25 8:05:08 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by RAPT Therapeutics Inc.

      SCHEDULE 13G - RAPT Therapeutics, Inc. (0001673772) (Subject)

      4/30/25 11:11:52 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by RAPT Therapeutics Inc.

      DEFA14A - RAPT Therapeutics, Inc. (0001673772) (Filer)

      4/14/25 8:38:22 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by RAPT Therapeutics Inc.

      DEF 14A - RAPT Therapeutics, Inc. (0001673772) (Filer)

      4/14/25 8:35:51 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by RAPT Therapeutics Inc.

      PRE 14A - RAPT Therapeutics, Inc. (0001673772) (Filer)

      4/4/25 5:04:49 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - RAPT Therapeutics, Inc. (0001673772) (Filer)

      3/27/25 4:10:08 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by RAPT Therapeutics Inc.

      S-8 - RAPT Therapeutics, Inc. (0001673772) (Filer)

      3/6/25 9:04:02 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by RAPT Therapeutics Inc.

      10-K - RAPT Therapeutics, Inc. (0001673772) (Filer)

      3/6/25 8:07:22 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RAPT Therapeutics, Inc. (0001673772) (Filer)

      3/6/25 8:05:11 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    RAPT Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RAPT Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded RAPT Therapeutics from Neutral to Buy and set a new price target of $10.00

      12/26/24 7:14:12 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded RAPT Therapeutics from Buy to Hold and set a new price target of $2.00 from $7.00 previously

      11/13/24 8:21:31 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded RAPT Therapeutics from Overweight to Neutral and set a new price target of $2.00 from $8.00 previously

      11/11/24 3:23:02 PM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics downgraded by JP Morgan

      JP Morgan downgraded RAPT Therapeutics from Neutral to Underweight

      11/11/24 11:46:41 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics downgraded by Wolfe Research

      Wolfe Research downgraded RAPT Therapeutics from Outperform to Peer Perform

      5/14/24 8:02:37 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics downgraded by Guggenheim

      Guggenheim downgraded RAPT Therapeutics from Buy to Neutral

      5/10/24 7:47:32 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics downgraded by Barclays with a new price target

      Barclays downgraded RAPT Therapeutics from Overweight to Equal Weight and set a new price target of $4.00 from $13.00 previously

      5/10/24 7:47:11 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics downgraded by UBS with a new price target

      UBS downgraded RAPT Therapeutics from Buy to Neutral and set a new price target of $10.00 from $61.00 previously

      2/22/24 6:26:24 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded RAPT Therapeutics from Outperform to Market Perform and set a new price target of $10.00 from $42.00 previously

      2/21/24 7:10:09 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics downgraded by JP Morgan with a new price target

      JP Morgan downgraded RAPT Therapeutics from Overweight to Neutral and set a new price target of $15.00 from $35.00 previously

      2/21/24 6:27:34 AM ET
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care